Skip to main content

Advertisement

Table 4 Pt, As, and Se amounts in 24-h urine as metal · (g creatinine) -1 results for the group patients treated with Pt-based drugs and control group treated without Pt-based drug and the baseline group (a)

From: Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs

Groups Type of cancer Parameter μg Pt/g Cr μg Se/g Cr ng As/g Cr
Cisplatin (Group 1) Lung X 1.05 143.0 5.57
Med 1.06 49.0 2.08
DS 0.625 263.0 8.94
n 32 24 21
Min 0.136 7.0 0.360
Max 2.52 1028.0 31.1
Cisplatin (Group 2) Other X 1.39 83.9 7.96
Med 0.969 40.7 2.55
DS 1.59 186.0 17.1
n 47 36 31
Min 0.110 11.3 0.280
Max 7.26 1136.0 91.2
Carboplatin (Group 3) Other X 13.3 156.0 10.1
Med a a a
DS 9.76 182.0 18.5
n 11 9 6
Min 0.780 25.5 0.40
Max 32.5 484.0 47.7
Control 1 (b) (Group 4) Other X   51.6  
Med   a  
DS   33.7  
n   7  
Min   5.30  
Max   92.3  
Control 2 (c) (Group 5) Lung and other X   61.9  
   Med   a  
   DS   20.4  
   n   9  
   Min   28.1  
   Max   90.4  
  1. Pt, As and Se amounts in 24-h urine samples expressed as metal (g creatinine)–1
  2. Supp, Supplied; X, mean; Med, Median; SD, Standard deviation; n, number of cases; Min, Minimum value; Max, Maximum value; (a) due the small number of cases, the median values were not reported; (b) non platinum drugs treatment; (c) patients without chemotherapy (two gastric cancer, two bladder cancer and five lung cancer).